Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

Ascletis Pharma (China) Co., Limited · NCT07842640

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
84
US sites recruiting
1
Study start
August 27, 2026
Record last updated
September 25, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection

Being studied: ASC35 Injection B, for subcutaneous use; ASC35 Placebo Injection B, for subcutaneous use; Tirzepatide

Conditions: Chronic Weight Management

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have given written informed consent to participate in this study in accordance with local regulations and the Institutional Review Boards (IRB) governing the study site.
  • Are between 18 and 65 years of age (both inclusive) at time of screening.
  • No clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and other screening procedures.

Exclusion Criteria

  • Have evidence of any clinically significant active or chronic disease.
  • Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), history of ketoacidosis, or hyperosmolar state/coma.
  • Have an autoimmune disease, is immunosuppressed or is in any way immunocompromised.
  • Have a history of acute or chronic pancreatitis.
  • Have a known clinically significant gastric emptying abnormality.
  • Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy.
  • Have a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the Investigator, may preclude the participant from following and completing the protocol.

Recruiting US locations

  • Ascletis Clinical Site

    Baltimore, MD 21201

    Site contact: Ascletis Recruiting · clinicaltrials@ascletis.com

Study contacts (from the official record)

  • Ascletis Recruiting · +1 2068073688 · clinicaltrials@ascletis.com
All weight loss studies in Maryland →
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics,… (NCT07842640) | Bored Studies